首页> 外文期刊>中国医学科学杂志(英文版) >Bone Marrow Urokinase Plasminogen Activator Receptor Levels are Associated with the Progress of Multiple Myeloma△
【24h】

Bone Marrow Urokinase Plasminogen Activator Receptor Levels are Associated with the Progress of Multiple Myeloma△

机译:骨髓尿激酶纤溶酶原激活物受体水平与多发性骨髓瘤的进展有关

获取原文
获取原文并翻译 | 示例
       

摘要

Objective To determine the mRNA and protein levels of urokinase plasminogen activator receptors (uPAR) in bone marrow fluid and bone marrow tissue from multiple myeloma (MM) patients and assess association of uPAR level with prognosis of MM. Methods uPAR levels in bone marrow fluid of 22 MM patients at the stable and progressive stages and 18iron deficiency anemia patients with normal bone marrow (control) were examined by ELISA. Furthermore, uPAR expression in bone marrow tissue was investigated by RT-PCR and Western blot, respectively. The distribution of uPAR in MM cells was examined using immunofluorescence staining. The pathological changes in different stages of MM patients were studied by HE staining. Results uPAR level in bone marrow fluid of MM patients (1.52±0.32μg/ml) was found to be higher than that in the control group (0.98±0.15μg/ml). Interestingly, uPAR protein (0.686±0.075vs. 0.372±0.043, P<0.05) and mRNA (2.51±0.46vs. 4.46±1.15,P<0.05) expression levels of MM patients at the progressive stage were significantly higher than those at the stable stage. The expression of uPAR in MM bone marrow was confirmed by immunofluorescence staining.Moreover, HE staining revealed a great increased number of nucleated cells and severe impairment of hematopoietic function in the bone marrow of patients with progressive-stage myeloma. Conclusion Our study reveals that uPAR expression is positively correlated with the development and progress of MM.
机译:目的确定多发性骨髓瘤(MM)患者骨髓液和骨髓组织中尿激酶纤溶酶原激活物受体(uPAR)的mRNA和蛋白水平,并探讨uPAR水平与MM预后的关系。方法采用ELISA法检测22例MM患者稳定期和进展期骨髓液中uPAR水平,以及正常骨髓(对照)18例铁缺乏症贫血患者的uPAR水平。此外,分别通过RT-PCR和Western印迹研究了uPAR在骨髓组织中的表达。使用免疫荧光染色检查uPAR在MM细胞中的分布。通过HE染色研究了MM患者不同阶段的病理变化。结果MM患者骨髓液中的uPAR水平为1.52±0.32μg/ ml,高于对照组的0.98±0.15μg/ ml。有趣的是,进展期MM患者的uPAR蛋白(0.686±0.075vs.0.372±0.043,P <0.05)和mRNA(2.51±0.46vs.4.46±1.15,P <0.05)表达水平显着高于MM患者。稳定的阶段。免疫荧光染色证实了uPAR在MM骨髓中的表达。此外,HE染色显示进展期骨髓瘤患者的骨髓中有核细胞数量大量增加,造血功能严重受损。结论我们的研究表明,uPAR表达与MM的发展和进程呈正相关。

著录项

  • 来源
    《中国医学科学杂志(英文版)》 |2016年第3期|155-160|共6页
  • 作者单位

    Department of Hematology, Huzhou Central Hospital, Huzhou, Zhejiang 313003, China;

    Department of Hematology, Huzhou Central Hospital, Huzhou, Zhejiang 313003, China;

    Department of Hematology, Huzhou Central Hospital, Huzhou, Zhejiang 313003, China;

    Department of Hematology, Huzhou Central Hospital, Huzhou, Zhejiang 313003, China;

    Department of Hematology, Huzhou Central Hospital, Huzhou, Zhejiang 313003, China;

    Department of Hematology, Huzhou Central Hospital, Huzhou, Zhejiang 313003, China;

  • 收录信息 中国科学引文数据库(CSCD);中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号